KYTX (Kyverna Therapeutics) EBIT per Share : $-3.45 (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics EBIT per Share?

Kyverna Therapeutics's EBIT per Share for the three months ended in Dec. 2024 was $-0.87. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-3.45.

During the past 3 years, the average EBIT per Share Growth Rate was -53.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Kyverna Therapeutics's EBIT per Share or its related term are showing as below:

KYTX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -53.9 Med: -53.9 Max: -53.9
Current: -53.9

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Kyverna Therapeutics was -53.90% per year. The lowest was -53.90% per year. And the median was -53.90% per year.

KYTX's 3-Year EBIT Growth Rate is ranked worse than
93.59% of 1233 companies
in the Biotechnology industry
Industry Median: 8 vs KYTX: -53.90

Kyverna Therapeutics's EBIT for the three months ended in Dec. 2024 was $-37.46 Mil.

Kyverna Therapeutics EBIT per Share Historical Data

The historical data trend for Kyverna Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics EBIT per Share Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

EBIT per Share

-1.02

-1.12

-1.47

-3.32

Kyverna Therapeutics Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial					-0.51	-1.12	-0.67	-0.80	-0.87

Kyverna Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Kyverna Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-127.335	/	38.335
=	-3.32

Kyverna Therapeutics's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-37.462	/	43.232
=	-0.87

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.45

Kyverna Therapeutics (NAS:KYTX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Kyverna Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.